Depo-SubQ Provera 104 Shortage Update: What Patients Need to Know in 2026

Patients relying on Depo-SubQ Provera 104 for contraception or endometriosis pain management have had a lot to process since late 2025. Between pharmacy stocking challenges and a major FDA label update in December 2025, many are wondering: is this drug in shortage? Is it safe? And what should I do? This article answers those questions with the latest facts.

Is Depo-SubQ Provera 104 in Shortage in 2026?

No — as of 2026, Depo-SubQ Provera 104 is not listed on the FDA Drug Shortage Database. Pfizer continues to manufacture the product and the national supply of medroxyprogesterone acetate injectable remains intact.

What patients are experiencing is inconsistent retail pharmacy stocking — not a true shortage. Because Depo-SubQ Provera 104 is a brand-only injectable given only once every three months, many retail pharmacies don't keep it in stock routinely. They order it on demand, which can cause a 1–3 day delay for patients who show up expecting it to be on the shelf.

The December 2025 FDA Meningioma Warning: What Happened?

In December 2025, the FDA approved an important update to the prescribing information for Depo-SubQ Provera 104 (and Depo-Provera CI). The label now includes a warning about a possible increased risk of meningioma — a typically benign brain tumor — associated primarily with long-term use of injectable medroxyprogesterone acetate.

This change was driven by data from a large BMJ study that found an approximately 5.6-fold increase in odds of surgically treated meningioma with prolonged use of injectable medroxyprogesterone, and a JAMA Neurology study showing a roughly 2-fold increased risk in users. The warning applies to both the subcutaneous (Depo-SubQ Provera 104) and intramuscular (Depo-Provera CI) formulations.

Is Depo-SubQ Provera 104 Safe to Use in 2026?

The FDA did not recall or restrict Depo-SubQ Provera 104. The drug remains approved and available. The absolute risk of meningioma remains low, especially for short-term or moderate-term users. Here is what the updated guidance says:

The meningioma risk is associated primarily with long-term use (generally more than 1 year, with the highest risk at 4+ years).

Depo-SubQ Provera 104 was already not recommended for use longer than 2 years (due to bone density concerns). This longstanding guidance aligns with the meningioma risk timeline.

Patients with a personal or family history of meningioma should discuss risks with their provider before continuing use.

If you use Depo-SubQ Provera 104 and experience new symptoms such as persistent headaches, vision changes, hearing loss, or seizures, contact your provider promptly.

What Does This Mean for Ongoing Prescriptions?

For most short-term users — especially those using it for 1–2 years or less — the benefit-to-risk ratio remains favorable. For long-term users (3+ years), this is a conversation worth having with your doctor to review alternatives. The existing guidance already recommended keeping use under 2 years unless no other adequate options are available.

38,404+ patients found their medications in stock

38K+

Find Depo-SubQ Provera 104 In Stock Today →

What Should You Do If You Can't Find It at Your Pharmacy?

If your pharmacy is out of stock, don't panic — the supply is there, it's just a stocking issue. Call your OB/GYN or women's health clinic first, as most administer the injection in-office. You can also use medfinder to find which pharmacies near you currently have it in stock without having to make calls yourself.

The Bottom Line for Patients in 2026

No formal FDA shortage — the drug is available nationally.

Meningioma warning added December 2025, but the drug was not recalled.

Risk is primarily associated with long-term use; already recommended for no more than 2 years.

Pharmacy availability is inconsistent; call your OB/GYN or use medfinder to locate stock near you.

If you want to explore alternatives, read our full guide on alternatives to Depo-SubQ Provera 104 to discuss options with your doctor.